Warning letter
Pine Pharmaceuticals, LLC: warning letter of Nov 7, 2016
FDA warning letter 500724 · New York District Office
Key facts
| Reference number | 500724 |
|---|---|
| Company | Pine Pharmaceuticals, LLC |
| Subject | Unapproved New Drug/Compounding/Misbranding/Adulterated |
| Issue date | Nov 7, 2016 |
| Posted date | Nov 22, 2016 |
| Issuing office | New York District Office |
| Product type | Drugs |
| CFR sections cited | 201.115, 211.192, 200.10(b), 211.165(a), 210.1(b) |
| Inspection city | Tonawanda |
| Inspection ZIP | 14150 |
| Inspection start date | Oct 5, 2015 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: